-
EP2776054
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2776054
| EP2776054 - ANTAGONISTS FOR ABNORMAL VASOPRESSIN V2 RECEPTOR AND USES THEREOF [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 06.10.2017 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 27.06.2017 | Most recent event Tooltip | 06.10.2017 | Application deemed to be withdrawn | published on 08.11.2017 [2017/45] | Applicant(s) | For all designated states Woomera Therapeutics 115 Etna Road Lebanon, NH 03766 / US | [2014/38] | Inventor(s) | 01 /
NORTH, William, G. 34 Low Road Hanover, NH 03755 / US | 02 /
PANG, Roy, H.L. 15 Partridge Road Etna, NH 03750 / US | [2014/38] | Representative(s) | Potter Clarkson Chapel Quarter Mount Street Nottingham NG1 6HQ / GB | [N/P] |
| Former [2014/38] | Potter Clarkson LLP The Belgrave Centre Talbot Street Nottingham, NG1 5GG / GB | Application number, filing date | 12847732.0 | 09.11.2012 | WO2012US64348 | Priority number, date | US201161559004P | 11.11.2011 Original published format: US 201161559004 P | [2014/38] | Filing language | EN | Procedural language | EN | Publication | Type: | A2 Application without search report | No.: | WO2013071038 | Date: | 16.05.2013 | Language: | EN | [2013/20] | Type: | A2 Application without search report | No.: | EP2776054 | Date: | 17.09.2014 | Language: | EN | The application published by WIPO in one of the EPO official languages on 16.05.2013 takes the place of the publication of the European patent application. | [2014/38] | Search report(s) | International search report - published on: | KR | 08.08.2013 | (Supplementary) European search report - dispatched on: | EP | 21.07.2015 | Classification | IPC: | A61K38/08, A61K39/395, A61P35/00 | [2014/38] | CPC: |
C07K16/2869 (EP,US);
A61K38/31 (EP,US);
A61K39/3955 (US);
A61K45/06 (US);
A61K49/0058 (US);
A61K51/1036 (US);
A61K51/1063 (EP,US);
A61K51/1096 (EP,US);
A61P35/00 (EP);
C07K14/4703 (EP,US);
C07K14/72 (US);
C07K16/26 (EP,US);
C07K7/06 (US);
G01N33/57492 (US);
A61K2039/505 (EP,US);
A61K2039/507 (US);
A61K38/00 (EP,US);
C07K2317/34 (EP,US);
| C-Set: |
A61K38/31, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/38] | Title | German: | ANTAGONISTEN FÜR DEN ANORMALEN VASOPRESSIN-V2-REZEPTOR UND SEINE VERWENDUNGEN | [2014/38] | English: | ANTAGONISTS FOR ABNORMAL VASOPRESSIN V2 RECEPTOR AND USES THEREOF | [2014/38] | French: | ANTAGONISTES D'UN RÉCEPTEUR DE LA VASOPRESSINE V2 ANORMAL ET UTILISATIONS ASSOCIÉES | [2014/38] | Entry into regional phase | 05.06.2014 | National basic fee paid | 05.06.2014 | Search fee paid | 05.06.2014 | Designation fee(s) paid | 05.06.2014 | Examination fee paid | Examination procedure | 05.06.2014 | Examination requested [2014/38] | 04.02.2016 | Amendment by applicant (claims and/or description) | 01.06.2017 | Application deemed to be withdrawn, date of legal effect [2017/45] | 28.06.2017 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2017/45] | Fees paid | Renewal fee | 26.11.2014 | Renewal fee patent year 03 | 10.11.2015 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 30.11.2016 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [E]EP2657336 (OTSUKA PHARMA CO LTD [JP]) [E] 14,15 * abstract * * paragraph [0016]; sequence 1 *; | [X]US2005019841 (GARMAN JONATHAN DAVID [US], et al) [X] 14 * abstract * * page 98; table 3 *; | [Y]WO2009137113 (WOOMERA THERAPEUTICS INC [US], et al) [Y] 1-15 * the whole document * | [XY] - WILLIAM G. NORTH ET AL, "MCF-7 breast cancer cells express normal forms of all vasopressin receptors plus an abnormal V2R*", PEPTIDES, (19990801), vol. 20, no. 7, doi:10.1016/S0196-9781(99)00070-4, ISSN 0196-9781, pages 837 - 842, XP055199696 [X] 12,14 * the whole document * [Y] 1-15 DOI: http://dx.doi.org/10.1016/S0196-9781(99)00070-4 | [Y] - BOLIGNANO D ET AL, "Aquaretic inhibits renal cancer proliferation: Role of vasopressin receptor-2 (V2-R)", UROLOGIC ONCOLOGY, ELSEVIER, NEW YORK, NY, US, vol. 28, no. 6, doi:10.1016/J.UROLONC.2008.12.014, ISSN 1078-1439, (20101101), pages 642 - 647, (20090214), XP027481368 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.urolonc.2008.12.014 | International search | [X]US2008050376 (NORTH WILLIAM G [US], et al); | [A]US7018812 (OAKLEY ROBERT H [US], et al); | [X] - GENEBANK, (19971201), Database accession no. AAB87678, XP003033741 | [A] - FAY, M. J. ET AL., "Evidence for expression of vasopressin V2 receptor mRNA in human lung", PEPTIDES, (1996), vol. 17, no. 3, pages 477 - 481, XP055082504 DOI: http://dx.doi.org/10.1016/0196-9781(96)00009-5 | [A] - VERBALIS, J. G., "Vasopressin V2 receptor antagonists", JOURNAL OF MOLECULAR ENDOCRINOLOGY, (2002), vol. 29, no. 1, pages 1 - 9, XP055082505 DOI: http://dx.doi.org/10.1677/jme.0.0290001 |